Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Total International Bond Index Fund ETF (BNDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Total International Bond Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Vanguard Total International Bond Index Fund ETF trades at $47.84. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | BNDX | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $49.91 |
52-Week Low | $10.24 | $47.57 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BNDX is trading at $48.02, down 0.46% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure. The ETF maintains consistent dividend distributions of $0.11 per share scheduled through mid-2026. Current market sentiment reflects uncertainty around Federal Reserve policy direction, with bond ETF flows showing increased investor interest in fixed income amid stock market volatility.
The outlook for BNDX remains tied to interest rate expectations and bond market dynamics. While the ETF offers income stability through regular dividends, potential Fed rate hikes could pressure bond prices. Investors seeking reliable income may find value, but should monitor monetary policy developments closely given the current bearish technical setup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →
